Optimal management of pulmonary metastases from colorectal cancer.


:The incidence of colorectal cancers is rising worldwide and pulmonary metastases were seen in approximately 10-15% of all patients. Surgical metastasectomy is a widely accepted procedure in selected patients and is considered as the only curative option in patients with secondary pulmonary malignancy. But surgical resection remains controversial due to the lack of randomized trials, comparing pulmonary metastasectomy to control, either medical therapy, or observation. This article will discuss the differentiated therapeutic strategies for patients with pulmonary metastases of colorectal cancer, focusing on surgical resection, patient evaluation, prognostic factors, interdisciplinary therapeutic approaches and current trials.


Limmer S,Unger L




Has Abstract


2011-10-01 00:00:00












  • Salvage of local recurrence after primary thermal ablation for small renal masses.

    abstract::The management of renal tumors has evolved rapidly over the last two decades, with the ascendance of nephron-sparing surgery (NSS), largely spurred by the increased incidental detection of small renal masses (SRMs) and evidence that preservation of renal parenchyma reduces the risk of chronic kidney disease. The field...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Nguyen CT,Campbell SC

    更新日期:2008-12-01 00:00:00

  • Capecitabine in the treatment of colorectal cancer.

    abstract::Capecitabine is an oral prodrug of 5-fluorouracil. It is being increasingly used in the treatment of colorectal cancer in both the adjuvant and metastatic settings. This review aims to explore the data in relation to the pharmacology and mode of action of capecitabine, followed by an in-depth review of the available c...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Kelly C,Cassidy J

    更新日期:2007-06-01 00:00:00

  • Can diet prevent nonmelanoma skin cancer progression?

    abstract::Nonmelanoma skin cancer is the most prevalent malignant disease among light-skinned individuals in the USA, accounting for approximately 1 million new cases annually. Solar ultraviolet radiation is known to be the major cause of skin cancer. The idea that diet, particularly dietary fat, may play a role in modulating c...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Black HS

    更新日期:2005-10-01 00:00:00

  • Chemoprevention of prostate cancer.

    abstract::Dietary factors and other naturally occurring substances may emerge as potent therapeutic or preventative agents in the battle against prostate cancer. Much of the current support for these agents is epidemiologically based, but new prospective studies are now underway which may support their use in conventional medic...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Ward JF,Blute ML

    更新日期:2003-04-01 00:00:00

  • Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.

    abstract::Acute myeloid leukemia (AML) is a hematologic malignancy with a peak incidence over the age of 55 years. AML of older patients is less curable with conventional chemotherapy, and, when it relapses, is almost uniformly fatal. Novel treatments hold the promise of improving the results of therapy, but have failed so far ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Lekakis L,de Lima M

    更新日期:2008-05-01 00:00:00

  • Venous thromboembolism and malignancy.

    abstract::The association between venous thromboembolism (VTE) and malignancy was first recognized more than 135 years ago. Since then, a markedly increased incidence of VTE has been found in patients with malignant disease. Numerous clinical studies have demonstrated that malignancy or its treatment are major risk factors for ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Gao S,Escalante C

    更新日期:2004-04-01 00:00:00

  • Unresolved issues in diffuse large B-cell lymphomas.

    abstract::For more than 25 years, the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was considered the 'gold standard' for the treatment of aggressive lymphomas, 90% of which are diffuse large B-cell lymphomas (DLBCLs). After the demonstration of rituximab's single-agent activity in DLBCL, a pi...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Murawski N,Zwick C,Pfreundschuh M

    更新日期:2010-03-01 00:00:00

  • Kaposi sarcoma as a model of oncogenesis and cancer treatment.

    abstract::Kaposi sarcoma is the most common cancer among HIV-infected individuals and one of the most common cancers in sub-Saharan Africa. Kaposi sarcoma lesions are highly vascularized, and comprised of spindle-shaped tumor cells. Kaposi sarcoma herpesvirus is etiologically linked to Kaposi sarcoma development and encodes gen...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Hansen A,Boshoff C,Lagos D

    更新日期:2007-02-01 00:00:00

  • Response to systemic therapy in locally advanced and metastatic renal cell carcinoma: can it be predicted?

    abstract:INTRODUCTION:: Renal cell carcinoma is no longer considered a monolithic disease, but a group of different entities exhibiting unique molecular alterations requiring a tailored systemic approach. One of the remaining challenges is the identification of the best candidate for a particular therapeutic regimen. AREAS COV...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章


    authors: González J,Gaynor JJ,Ciancio G

    更新日期:2021-01-29 00:00:00

  • Treatment of newly diagnosed diffuse brain stem gliomas in children: in search of the holy grail.

    abstract::Diffuse brain stem glioma is the most devastating of pediatric malignancies. Virtually all children with this disease die within 1-2 years of diagnosis. After three decades of exhaustive research, the key to controlling this malignancy still eludes us. Attempts to improve survival using radiation, chemotherapy and bio...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Korones DN

    更新日期:2007-05-01 00:00:00

  • Emerging data on improving response to hormone therapy: the role of novel targeted agents.

    abstract:INTRODUCTION:Hormone receptor positive (HR+) breast cancer represents the most common subtype of breast cancer. Metastatic HR+ breast cancer may develop resistance to standard hormone therapies, arising from genomic alterations in the estrogen receptor and/or upregulation of other signal transduction pathways. Areas co...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Vidula N,Rugo HS

    更新日期:2018-01-01 00:00:00

  • Current radiotherapy techniques in NSCLC: challenges and potential solutions.

    abstract::Introduction: Radiotherapy is an important therapeutic strategy in the management of non-small cell lung cancer (NSCLC). In recent decades, technological implementations and the introduction of image guided radiotherapy (IGRT) have significantly increased the accuracy and tolerability of radiation therapy.Area covered...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章


    authors: Giaj-Levra N,Borghetti P,Bruni A,Ciammella P,Cuccia F,Fozza A,Franceschini D,Scotti V,Vagge S,Alongi F

    更新日期:2020-05-01 00:00:00

  • TIM-3 pathway dysregulation and targeting in cancer.

    abstract:INTRODUCTION:Dysfunction of the immune system is a hallmark of cancer. Through increased understanding of the complex interactions between immunity and cancer, immunotherapy has emerged as a treatment modality for different types of cancer. Promising activity with immunotherapy has been reported in numerous malignancie...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章


    authors: Zeidan AM,Komrokji RS,Brunner AM

    更新日期:2021-01-19 00:00:00

  • Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.

    abstract::Pegylated liposomal doxorubicin (PLD) was first approved for platinum-refractory ovarian cancer in 1999 and then received full approval for platinum-sensitive recurrent disease in 2005 by the US FDA. PLD remains an important therapeutic tool in the management of recurrent ovarian cancer in 2012. Phase-II and III clini...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Rakowski JA,Ahmad S,Holloway RW

    更新日期:2012-01-01 00:00:00

  • Determining treatment intensity in elderly patients with multiple myeloma.

    abstract:INTRODUCTION:In the majority of cases, multiple myeloma is a disease occurring in elderly patients. In the last decades, a major improvement in myeloma patients' outcome has been achieved with the introduction of several new drugs. However, this positive outcome was less likely to occur in elderly patients. Areas cover...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Salvini M,D'Agostino M,Bonello F,Boccadoro M,Bringhen S

    更新日期:2018-09-01 00:00:00

  • Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management.

    abstract:INTRODUCTION:Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of breast or ovarian carcinoma. STIC is a pa...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Weinberger V,Bednarikova M,Cibula D,Zikan M

    更新日期:2016-12-01 00:00:00

  • Current, new and novel therapy for castration-resistant prostate cancer.

    abstract::Androgen deprivation therapy is the standard of care for the initial treatment of metastatic prostate cancer. However, the majority of these patients live long enough to experience disease progression despite castration. This scenario is defined as castration-resistant prostate cancer (CRPC) and has a poor outcome and...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Gaya JM,Ahallal Y,Sanchez-Salas R,Barret E,Rozet F,Galiano M,Macek P,Durand M,Cerruti J,Prapotnich D,Ropert S,Bennamoun M,Cathelineau X

    更新日期:2013-07-01 00:00:00

  • Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma.

    abstract::According to computed tomography image analysis, skeletal muscle (SM) and adipose tissue areas vary widely in patients with the same body mass index or the same body surface area. Body composition variables such as SM mass, SM density and subcutaneous and visceral adipose tissue have shown value as potential independe...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Antoun S,Lanoy E,Albiges-Sauvin L,Escudier B

    更新日期:2014-03-01 00:00:00

  • Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.

    abstract::The year 2006 will mark a turning point in the daily management of patients with metastatic renal cell carcinoma. The impact of immunotherapy with interferon-alpha or interleukin-2 has been shown to be restricted to a minority of patients. The growing understanding of molecular mechanisms involved in the pathogenesis ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Pouessel D,Culine S

    更新日期:2006-12-01 00:00:00

  • Tumor heterogeneity: does it matter?

    abstract::Introduction: It has long been recognized that tumors are composed of a mosaic of cells and numerous methods have been developed to detect tumor heterogeneity, including in situ hybridization, multi-regional sampling, cytological assays, and whole genome and single cell sequencing. Using these methods, heterogeneity h...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Turnquist C,Watson RA,Protheroe A,Verrill C,Sivakumar S

    更新日期:2019-10-01 00:00:00

  • Molecular markers of chemotherapeutic response and toxicity in colorectal cancer.

    abstract::Outcomes in colorectal cancer have improved over the last 15 years; this is in part due to the optimization of 5-fluorouracil schedules and the introduction of new and effective chemotherapeutic agents, such as irinotecan and oxaliplatin. However, not all patients respond to these agents and a proportion may suffer se...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Braun MS,Quirke P,Seymour MT

    更新日期:2007-04-01 00:00:00

  • The multidisciplinary management of giant cell tumor of bone.

    abstract::Giant cell tumor of bone is a locally aggressive lesion with a predilection for local recurrence, and in a small proportion of patients, metastatic disease can develop. Surgery is the mainstay of management for extremity-based lesions. For tumors located in challenging anatomical locations such as the sacrum and spine...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Ng VY,Davidson DJ,Kim EY,Pollack SM,Conrad Iii EU,Jones RL

    更新日期:2014-07-01 00:00:00

  • Clinical outcome after cystectomy in patients with lymph node-positive bladder cancer.

    abstract::Whereas radical cystectomy is the standard of care in high-grade, invasive bladder tumors, the extent of lymphadenectomy and its diagnostic and/or therapeutic potential is controversial. Independent predictors for lymph node involvement are T-stage, histological grading and lymphovascular invasion. Preoperative assess...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Nagele U,Anastasiadis AG,Merseburger AS,Sievert KD,Stenzl A,Kuczyk M

    更新日期:2006-06-01 00:00:00

  • Darbepoetin alfa for the treatment of cancer-related anemia: an update.

    abstract::Anemia is a common and potentially debilitating complication of cancer. Darbepoetin alfa (Aranesp, Amgen) has been in routine clinical use for the treatment of chemotherapy-induced anemia since 2002. The extended half-life of darbepoetin alfa permits less frequent and consequently more flexible dosing than other eryth...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Pirker R

    更新日期:2004-10-01 00:00:00

  • Statistical approaches for evaluating body composition markers in clinical cancer research.

    abstract:INTRODUCTION:The term 'morphomics' stands for the markers of body composition in muscle and adipose tissues. in recent years, as part of clinical cancer research, several associations between morphomics and outcome or toxicity were found in different treatment settings leading to a growing interest. we aim to review st...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Bayar MA,Antoun S,Lanoy E

    更新日期:2017-04-01 00:00:00

  • A model for the regulation of T-type Ca(2+) channels in proliferation: roles in stem cells and cancer.

    abstract::Ca(2+) influx at critical points in the cell cycle is required for proliferation. This requirement is so ubiquitous that its occurrence is often treated as background noise. Yet without it, cells stop dividing, suggesting an obvious and potentially effective way to treat cancer. To control proliferation by controlling...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Gray LS,Schiff D,Macdonald TL

    更新日期:2013-05-01 00:00:00

  • Advances in radiation therapy of head and neck cancer.

    abstract::Head and neck cancer is the fifth most common cancer in the USA. Although there have been major improvements in surgical and radiation techniques, the overall survival has not changed significantly in the last decade. The major changes occurring in recent years have been in the ability to preserve organs and to improv...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Popovtzer A,Eisbruch A

    更新日期:2008-04-01 00:00:00

  • The role of stereotactic body radiotherapy and stereotactic radiosurgery in the re-irradiation of metastatic spinal tumors.

    abstract::Stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS) are advanced radiotherapy delivery techniques that allow for the delivery of high-dose per fraction radiation. Advances in imaging technology and intensity modulation have allowed SRS and SBRT to be used for the treatment of tumors in close prox...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Jain AK,Yamada YJ

    更新日期:2014-10-01 00:00:00

  • Review of management issues in relapsed osteosarcoma.

    abstract::Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. With combined modality treatment long-term survival rate for localized disease is near 70%. Thirty percent of patients relapse with lung as the commonest site. Surgery is the treatment of choice for relapsed patients whenever pos...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Vijayamurugan N,Bakhshi S

    更新日期:2014-02-01 00:00:00

  • Organ preservation strategies in bladder cancer.

    abstract::Bladder cancer is a significant cause of morbidity and mortality. Promising results with organ preservation strategies using multimodality treatment over the last decade offers an option for bladder preservation in a significant proportion of patients who currently undergo cystectomy. The primary goal of the bladder-s...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审


    authors: Hussain SA,James ND

    更新日期:2002-12-01 00:00:00